BRAF V600E mutation as a predictive factor of Anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: A meta-analysis

Chinese Medical Sciences Journal

Volumn 29, Issue 4, 2014, Pages 197-203

  Wang, Qi ^a   Hu, Wei Guo ^a   Song, Qi Bin ^a   Wei, Jia ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

BRAF; colorectal neoplasms; meta analysis

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PANITUMUMAB; B RAF KINASE; BRAF PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DETERIORATION; DRUG EFFICACY; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; META ANALYSIS; METASTATIC COLORECTAL CANCER; MUTANT; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE; COLORECTAL TUMOR; GENETICS; IMMUNOLOGY; METASTASIS; MUTATION; PATHOLOGY;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84919662543     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1001-9294(14)60070-5     Document Type: Article

References (29)

1. R Siegel, D Naishadham, A Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. JA Meyerhardt, RJ Mayer Systemic therapy for colorectal cancer N Engl J Med 352 2005 476 487
3. A Jemal, R Siegel, E Ward et al. Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
4. C Twelves, A Wong, MP Nowacki et al. Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2005 2696 2704
5. JP Kuebler, HS Wieand, MJ O'Connell et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 J Clin Oncol 25 2007 2198 2204
6. E Van Cutsem, CH Köhne, E Hitre et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
7. L Zhang, L Ma, Q Zhou Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis Int J Colorectal Dis 26 2011 1025 1033
8. HJ Lenz, E Van Cutsem, S Khambata-Ford et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 2006 4914 4921
9. LB Saltz, NJ Meropol, PJ Loehrer Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
10. A Walther, E Johnstone, C Swanton et al. Genetic prognostic and predictive markers in colorectal cancer Nat Rev Cancer 9 2009 489 499
11. T Ikenoue, Y Hikiba, F Kanai et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors Cancer Res 63 2003 8132 8137
12. F Di Nicolantonio, M Martini, F Molinari et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
13. F Loupakis, A Ruzzo, C Cremolini et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 2009 715 721
14. C Bokemeyer, E Van Cutsem, P Rougier et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 2012 1466 1475
15. JF Tierney, LA Stewart, D Ghersi et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007 Jun 7 [cited 2014 Apr 1]; 8:16 Available from: http://www.trialsjournal.com/content/8/1/16
16. JP Higgins, SG Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
17. JP Higgins, SG Thompson, JJ Deeks et al. Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
18. RF Galbraith A note on graphical presentation of estimated odds ratios from several clinical trials Stat Med 7 1988 889 894
19. M Egger, SG Davey, M Schneider et al. Bias in meta- analysis detected by a simple, graphical test BMJ 315 1997 629 634
20. P Laurent-Puig, A Cayre, G Manceau et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
21. A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009 Oct 2 [cited 2014 Apr 1]; 4:e7287 Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007287
22. W De Roock, B Claes, D Bernasconi et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
23. L Fornaro, GG Baldi, G Masi et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status Crit Rev Oncol Hematol 78 2011 243 251
24. J Souglakos, J Philips, R Wang et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 2009 465 472
25. Z Saridaki, M Tzardi, C Papadaki et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≤ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011 Jan 22 [cited 2014 Apr 1]; 6:e15980 Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0015980
26. JH Park, SW Han, DY Oh et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer Cancer Chemother Pharmacol 68 2011 1045 1055
27. P Ulivi, L Capelli, M Valgiusti et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. J Transl Med 2012 May 8 [cited 2014 Apr 1]; 10:87 Available from: http://www.translational-medicine.com/content/10/1/87
28. DP Modest, A Jung, N Moosmann et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial Int J Cancer 131 2012 980 986
29. C Mao, RY Liao, LX Qiu et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis Mol Biol Rep 38 2011 2219 2223